BrightHeart, a company developing AI tools for prenatal ultrasound, has closed an €11 million ($12.8 million) series A financing round.
The raised funds will support U.S. commercialization, expansion across Europe, and product innovation with the company's B-Right AI platform. BrightHeart's products provide ultrasound screening for complex organs, supporting ob/gyns in the detection of congenital defects and care for newborns. In 2025, the company received five clearances from the U.S. Food and Drug Administration (FDA).
The funding round was co-led by Odyssée Venture and GO Capital, with participation from the Mussallem CHD Alliance, Lift Value, IDAHO HealthTech Club via Side Angels, and founding investor Sofinnova Partners. It was also led by prominent clinicians and angel investors, including Laurent Salomon, MD, PhD, former president of the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG), and Sacha Loiseau and John Gridley, serial medtech entrepreneurs.
